Advertisement
Preferential rights issue in Prostatype Genomics
Rights issue for commercialization, Medicare approval and completed US study
The board of Prostatype Genomics has decided to carry out a preferential rights issue of up to 49.5 MSEK for the financing of continued commercialization in the company’s prioritised markets (the United States and selected EMEA markets), including the process for Medicare approval in the United States and the ongoing American validation study.
The guaranteed net proceeds are expected to be sufficient to apply for Medicare reimbursement approval for the genetic test Prostatype®, complete an ongoing American validation study and receive Medicare approval in the United States, all of these before the end of 2024.
The company considers receiving Medicare approval to be a crucial milestone to be able to achieve large-scale usage of Prostatype® in the United States, the world’s largest market for genetic tests in prostate cancer with annual sales of approx. 2 billion SEK. The reason is that the cost for each test would go from patient-financed to be covered by Medicare (currently approx. 3,700 USD per test).
The subscription period ends in:
Day(s)
:
Hour(s)
:
Minute(s)
:
Second(s)
Usage of the proceeds from the preferential rights issue
Prostatype Genomics is guaranteed to initially receive a minimum of approx. 35.7 MSEK in gross proceeds from the preferential rights issue and will receive a maximum of 49.5 MSEK. The net proceeds (after issue costs) of at least 27.5 MSEK will be allocated to the following activities:
- Repayment of bridge loan and interest (approx. 23 percent of the minimum net proceeds)
- Completed process to receive Medicare reimbursement approval and completion of the validation study in the United States (approx. 50 percent of the minimum net proceeds)
- Ongoing commercialization activities in the United States and Europe, and strengthening of the company’s overall working capital and ongoing operation activities (remaining part of the net proceeds)
The net proceeds from the exercise of included TO4 warrant, with exercise period November 25 – December 9, 2024, will also be used for commercialization activities in the United States and Europe, and strengthening of the company’s overall working capital and ongoing operation activities.
Prostatype Genomics is progressing as planned, with Q3 2024 marking the completion of the validation phase. This sets the stage for our biggest milestone in Q4: Medicare reimbursement approval.
LSIF is excited to be a lead guarantor in this offering. Considering the expected approval for reimbursement in the US in the near term, the next 6 – 12 months can radically change the prospects for Prostatype Genomics, and we look forward to supporting the company on this journey.
Commercial progress so far in 2024
Prostatype Genomics has achieved significant progress in its selected markets so far in 2024, including:
Commercial breakthrough in the United States
- Commercial availability of the genetic test Prostatype® in the United States, and initiated clinical use on patients, after achieving several regulatory milestones: laboratory agreement with ResearchDx, acquisition of a CLIA certificate and laboratory accreditation by CAP
- By holding its own CLIA certificate, the company can receive reimbursement payments directly from Medicare and commercial payers, which significantly increases the company’s potential sales income and profit margin in the United States
- Strategic collaboration and clinical use on patients with Professor E. David Crawford, MD, an internationally renowned expert within prostate cancer
- Continuous progress in the ongoing large American validation study with 1,200 patients and broad ethnicity coverage
Strong interim results from the long-term follow-up study in Uppsala
- The interim results from 180 of approx. 500 patients in total in the ongoing study at Akademiska University Hospital in Uppsala, Sweden showed excellent accuracy for Prostatype® even after 20 years of follow-up time after diagnosis
Positive final results from multicentre study with Prostatype® in Spain
- The retrospective study at seven hospitals, coordinated by the Spanish National Urology Association, showed that the treatment plan could have been modified for 39% of the patients if Prostatype® had been used as a decision basis
- Agreements signed with private healthcare providers in Spain, and ongoing negotiations with more private healthcare providers as well as university hospitals.
Timeline for the preferential rights issue
2024
Summary of the preferential rights issue
Subscription period
August 19 – September 2
Subscription price
0.01 SEK per share
Issue size
49.5 MSEK
Guaranteed up to
72.1 %
Preferential rights
Existing shareholders will receive one (1) unit right for each share held on the record date August 15, 2024. One (1) unit right entitles the holder to subscribe for one (1) unit in the company. Each unit consists of five (5) new shares and two (2) warrants of series TO 4.
Issue size
The rights issue comprises a maximum of 990,811,186 Units, corresponding to a maximum of 4,954,055,930 shares and 1,981,622,372 warrants of series TO 4. Upon full subscription in the rights issue, Prostatype Genomics will initially receive approximately 49.5 MSEK before deduction of issue costs.
Included warrants
One (1) warrant of series TO 4 entitles the holder to subscribe for one (1) new share in the company during the period November 25, 2024 to and including December 9, 2024 at an exercise price of 30% discount of the 10-day volume-weighted average price prior to the first day of the exercise period.
Record date
The last day of trading in the Prostatype Genomics share including the right to receive unit rights in the rights issue is August 13, 2024. The shares are traded excluding the right to receive unit rights in the rights issue from August 14, 2024.
Subscription price
The subscription price in the preferential rights issue is 0.05 SEK per unit, corresponding to 0.01 SEK per share. Warrants of series TO4 are issued free of charge.
Subscription period
The subscription period in the rights issue runs from August 19, 2024 to and including September 2, 2024.
Trading in warrants
Warrants of series TO 4 are expected to be admitted to trading on Nasdaq First North Growth Market in close connection with the registration of the rights issue with the Swedish Companies Registration Office and the conversion of BTU to ordinary shares and warrants.
Pre-subscriptions and guarantee commitments
The rights issue is covered by pre-subscriptions and guarantee commitments up to approx. 72.1 percent. The guarantee commitments consist partly of a so-called top guarantee commitments and partly of a so-called bottom guarantee commitments.
Conversion of shareholder loan
Shareholder loan of a total of 3.2 MSEK will be converted within the issue, or in a separate directed issue on identical terms as the rights issue.
Bridge loan
In order to secure the company’s liquidity needs until the rights issue has been completed, the company has obtained a bridge loan of 6.5 MSEK, where Exelity AB accounts for 4.2 MSEK and Buntel AB accounts for 2.3 MSEK.
Complete terms and conditions
The complete terms and conditions for the rights issue, including additional information about the company, is made available in an EU growth prospectus that was published on August 9, 2024.
Press releases and news
Press release September 23, 2024: Prostatype Genomics publishes newsletter on positive outlook in the US and selected EMEA markets
Press release September 13, 2024: Prostatype Genomics AB announces last day of trading in BTU and first day of trading in TO 4
Press release September 13, 2024: The Board of Directors of Prostatype Genomics AB decides on a directed issue to guarantors
Press release September 3, 2024: Prostatype Genomics AB’s rights issue was subscribed to 79.8 percent including guarantees and debt conversion
Press release August 27, 2024: Prostatype Genomics’ CEO on the road to Medicare approval in filmed company presentation
Press release August 19, 2024: The subscription period in Prostatype Genomics AB’s preferential rights issue of units begins today
Press release August 12, 2024: Prostatype® publishes update on concrete commercial progress in Spain
Press release August 9, 2024: Prostatype Genomics publishes prospectus due to upcoming preferential rights issue of units
Press release July 26, 2024: Prostatype Genomics publishes interim report for the first half of 2024
Press release July 16, 2024: Communiqué from extraordinary general meeting in Prostatype Genomics AB (Publ) held on 16 July 2024
Press release June 17, 2024: Notice of extraordinary general meeting in Prostatype Genomics AB (Publ)
Press release June 13, 2024: Prostatype Genomics carries out a rights issue of units of approximately 49.5 MSEK
Filmed company presentation
Send a question about the Rights Issue to Prostatype Genomics
IMPORTANT INFORMATION
This advertisement constitutes marketing and is not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council. The invitation to subscribe for securities in Prostatype Genomics AB (“Prostatype Genomics” or the “Company”) takes place only through the prospectus published in August 2024, which is available on Prostatype Genomics website www.prostatypegenomics.com. Investors are advised to read the prospectus in its entirety before making an investment decision. This advertisement may not be distributed, published or made public in or to the United States, Australia, Japan, Canada, New Zealand, South Africa, United Kingdom, Hong Kong, Switzerland or Singapore. The advertisement must not be sent to persons in these countries or any other jurisdiction to which it is prohibited to deliver subscription rights, BTA or new shares, except in accordance with applicable law and provided that it does not require any additional prospectus, registration or other actions beyond those that follow of Swedish law. Except as expressly stated otherwise in the prospectus, subscription rights, BTA or new shares may not be offered, sold, transferred or delivered, directly or indirectly, in or to any of these countries.
This advertisement is produced by the IR communications agency Honeybadger (owner of the domain ii.se) on behalf of Prostatype Genomics. Prostatype Genomics is thus the sender of the information in the advertisement and responsible for its correctness.